Arrowhead Pharmaceuticals, Inc. (arwr)
ARWR — Company Overview
Arrowhead Pharmaceuticals, Inc. (ARWR) is a mid-cap company in the Healthcare sector, operating in Biotechnology.
| Ticker | ARWR |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NMS |
| Market cap | $9.46B |
| Last price | $66.96 |
| Size category | Mid Cap |
ARWR — Business Description
Arrowhead Pharmaceuticals, Inc. (ARWR) operates in Biotechnology within the broader Healthcare market. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RA…
Official website: https://arrowheadpharma.com.
ARWR — Investment Thesis
The investment thesis for Arrowhead Pharmaceuticals, Inc. (ARWR) rests on how Healthcare dynamics, profitability, and valuation interact at today's price.
- Revenue is expanding at roughly 1.7% year-over-year (public data).
- Equity market capitalization is approximately $9.46B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
ARWR — Financial Health
Financial health for Arrowhead Pharmaceuticals, Inc. (ARWR) is summarized from publicly reported profitability, leverage, and cash-flow metrics.
Negative profit margin (-47.8%) signals near-term profitability pressure. Negative free cash flow of $-48.63M may require careful capital allocation. Debt-to-equity of 295.98 warrants monitoring in a higher-rate environment.
| Forward P/E | -13.94× |
| Price / Sales | 14.09× |
| Price / Book | 20.30× |
| Gross margin | 100.0% |
| Operating margin | -2.3% |
| Profit margin | -47.8% |
| Return on equity | -55.2% |
| Debt / Equity | 295.98 |
| Free cash flow | $-48.63M |
ARWR — Growth Outlook
Growth outlook for Arrowhead Pharmaceuticals, Inc. (ARWR) depends on demand trends in Biotechnology and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 1.7% indicates strong top-line momentum.
- Price is 29.9% below the 52-week high.
ARWR — Competitive Position
Arrowhead Pharmaceuticals, Inc. (ARWR) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Biotechnology.
- Market capitalization of $9.46B places ARWR among mid-cap peers.
- Gross margin near 100.0% may reflect pricing power or favorable mix.
ARWR — Strengths
Strengths for Arrowhead Pharmaceuticals, Inc. (ARWR) inferred from public financial metrics:
- Revenue growth of 1.7% year-over-year.
- Gross margin of 100.0% supports competitive unit economics.
ARWR — Weaknesses
Weaknesses and pressure points for Arrowhead Pharmaceuticals, Inc. (ARWR) based on available data:
- Thin profit margin (-47.8%).
- Negative free cash flow ($-48.63M).
- Elevated debt-to-equity (295.98).
- Price 30% below the 52-week high — sustained negative sentiment.
ARWR — Opportunities
- Sustained revenue growth (1.7%) could support multiple expansion if margins hold.
ARWR — Risks
- Leverage (debt/equity 295.98) raises sensitivity to credit conditions.
- Thin margins leave less room for operational missteps.
ARWR — Summary
Arrowhead Pharmaceuticals, Inc. (ARWR) is a mid-cap Healthcare company focused on Biotechnology, listed on NMS. Last price $66.96 with market cap $9.46B. Revenue grew 1.7% year-over-year per public data. Notable strengths include revenue growth of 1.7% year-over-year. Key watch items include thin profit margin (-47.8%). Public estimates and earnings snapshots for Arrowhead Pharmaceuticals, Inc. are on this site; ownership, live news, and deeper models remain in Vest Terminal.
Start Free — open ARWR in Vest Terminal
Access live data, filings, ownership, and analysis for Arrowhead Pharmaceuticals, Inc..
Arrowhead Pharmaceuticals, Inc. FAQ
What does Arrowhead Pharmaceuticals, Inc. (ARWR) do?
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in P…
What is ARWR's P/E ratio?
Arrowhead Pharmaceuticals, Inc. has a trailing P/E of N/A× based on publicly available market data.
Does ARWR pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is ARWR in?
Arrowhead Pharmaceuticals, Inc. is classified in Healthcare (Biotechnology) on NMS.
What is ARWR's market capitalization?
Approximate market cap: $9.46B.
What are the main risks for ARWR?
Key risks include above-average volatility (beta 1.28), among factors on this page.
What are the strengths of ARWR?
Potential positives include revenue growth of 1.7% year-over-year, gross margin of 100.0% supports competitive unit economics.
Where can I get analyst estimates for ARWR?
Public analyst price targets and consensus for Arrowhead Pharmaceuticals, Inc. are on the free /stocks/arwr/estimates page. Deeper estimate history and models are available in Vest Terminal.